GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yili Chuannig Biotechnology Co Ltd (SZSE:301301) » Definitions » Equity-to-Asset

Yili Chuannig Biotechnology Co (SZSE:301301) Equity-to-Asset : 0.69 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Yili Chuannig Biotechnology Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Yili Chuannig Biotechnology Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥7,320 Mil. Yili Chuannig Biotechnology Co's Total Assets for the quarter that ended in Mar. 2024 was ¥10,574 Mil. Therefore, Yili Chuannig Biotechnology Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.69.

The historical rank and industry rank for Yili Chuannig Biotechnology Co's Equity-to-Asset or its related term are showing as below:

SZSE:301301' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.45   Med: 0.53   Max: 0.69
Current: 0.69

During the past 6 years, the highest Equity to Asset Ratio of Yili Chuannig Biotechnology Co was 0.69. The lowest was 0.45. And the median was 0.53.

SZSE:301301's Equity-to-Asset is ranked better than
52.63% of 1556 companies
in the Biotechnology industry
Industry Median: 0.67 vs SZSE:301301: 0.69

Yili Chuannig Biotechnology Co Equity-to-Asset Historical Data

The historical data trend for Yili Chuannig Biotechnology Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yili Chuannig Biotechnology Co Equity-to-Asset Chart

Yili Chuannig Biotechnology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.45 0.47 0.50 0.60 0.69

Yili Chuannig Biotechnology Co Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.66 0.66 0.69 0.69

Competitive Comparison of Yili Chuannig Biotechnology Co's Equity-to-Asset

For the Biotechnology subindustry, Yili Chuannig Biotechnology Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yili Chuannig Biotechnology Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yili Chuannig Biotechnology Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Yili Chuannig Biotechnology Co's Equity-to-Asset falls into.



Yili Chuannig Biotechnology Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Yili Chuannig Biotechnology Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=6960.484/10138.649
=0.69

Yili Chuannig Biotechnology Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=7320.331/10573.869
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yili Chuannig Biotechnology Co  (SZSE:301301) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Yili Chuannig Biotechnology Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Yili Chuannig Biotechnology Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Yili Chuannig Biotechnology Co (SZSE:301301) Business Description

Traded in Other Exchanges
N/A
Address
No. 516, Almatua Village, Yining Park, Horgos Economic Development Zone, Xinjiang, Ili, CHN, 835000
Yili Chuannig Biotechnology Co Ltd adopts the most advanced and mature international biological fermentation, chemical extraction, enzymatic hydrolysis, control and energy saving, and environmental protection technology. The main products of the company include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, and crude ursodeoxycholic acid.

Yili Chuannig Biotechnology Co (SZSE:301301) Headlines

No Headlines